Compare Natera Inc. Common Stock (NTRA) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs T-Mobile Us Inc — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while T-Mobile Us Inc trades at $158.5 (market cap $164.91B). The key difference: T-Mobile Us Inc is far larger — about 2.9× Natera Inc. Common Stock's market cap, and T-Mobile Us Inc pays a 3.04% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and T-Mobile Us Inc for 84 Days on average.
| NTRA | TMUS | |
|---|---|---|
Market Cap | $57.03B | $164.91B |
Volume | 1,131,157 | 5,684,850 |
Sector | Health | Media |
52-Week High | $425.64 | $230.06 |
52-Week Low | $179.42 | $148.58 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $56.18B | $281.53B |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
T-Mobile US (TMUS) trades at $157.79, up 3.9% with strong recent earnings beats but faces technical bearish signals. The company maintains robust fundamentals with $88.31B revenue (2025), 11.45% net margin, and attractive valuation ratios (P/E 16.08, EV/EBITDA 8.73). Recent developments include a 15% dividend hike and AI-powered 5G network enhancements, though debt levels remain elevated at $84.6B.
TMUS presents a compelling growth story with solid profitability and analyst support (81% buy rating, $221.75 target), but investors must weigh technical weakness against fundamental strength. Key risks include competitive pressures, macroeconomic uncertainty, and the company's substantial debt load in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
